Navigation Links
Upcoming Corporate Presentations In San Francisco
Date:1/8/2016

SAN DIEGO, Jan. 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer, will provide a corporate overview at three upcoming healthcare conferences. Dr. Ji will present:

-  Late stage biosimilar and biobetter antibody programs, including Phase III results

-
Cell-internalizing antibody technology targeting mutant KRAS and other undruggable intracellular targets 

-
Immunocellular therapy and other programsEvent:2016 Biotech ShowcaseDate:Monday, January 11, 2016Time:9:00 a.m. to 9:30 a.m. PSTLocation:Powell Room, 3rd Floor, Parc 55 Hotel at 55 Cyril Magnin StreetEvent:9th Annual OneMedForumDate:Tuesday, January 12, 2016Time:11:00 a.m. to 11:15 a.m. PSTLocation:Club OneMed, Kensington Park Hotel at 450 Post StreetEvent:OneMed China ForumDate:Wednesday, January 13, 2016Time:2:45 p.m. to 3:00 p.m. PSTLocation:Club OneMed, Kensington Park Hotel at 450 Post Street

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Sorrento's prospects, including, but not limited to, any statements about its and its affiliates' technologies, including, but not limited to, the cell internalizing technology and combinations of the cell internalizing technology with Sorrento's antibody library; Sorrento's (and its subsidiaries' and affiliates') business and technology prospects; chimeric antigen receptor (CAR) T cell programs; potential combination therapies; Sorrento's expectations for adoptive cellular immunotherapies, cell internalizing technology; the development of adoptive immunotherapies and the biosimilar/biobetter programs; Sorrento's ability to leverage the expertise of its employees and partners to assist the company in the execution of its strategies; Sorrento's advances made in developing NK cell-based therapies, RTX and human monoclonal antibodies using its proprietary G-MAB fully human antibody technology, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento™, G-MAB™, CAR.TNK™, TNK Therapeutics™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2016 Sorrento Therapeutics

Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO

 


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. STAAR Surgical To Present At Upcoming Investor Conferences
2. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
3. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
4. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
5. GDS International Leads the Way for the Pharmaceutical Industry at its Upcoming NGP DD 30 Summit in Madrid
6. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
7. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
8. National Association of Specialty Pharmacy (NASP) Partners with the Patient Access Network (PAN) Foundation to Host Charity Golf Outing at Upcoming Meeting
9. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
10. Hologic to Present at Two Upcoming Investor Conferences
11. Amgen to Highlight New Data at Upcoming ESC Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2019)... , ... October 19, 2019 , ... Hospital M&A activity ... according to new acquisition data from HealthCareMandA.com. The most recent quarter was down 20% ... was up sharply compared with the second quarter, totaling nearly $5.0 billion, a 291% ...
(Date:10/17/2019)... ... October 17, 2019 , ... The findings of a ... in the individuals studied could be caused by toxic chemicals rather than the inhalation ... Illness Associated With E-Cigarette Use (Vaping): A Report of Eight Cases ,” by Sanjay ...
(Date:10/15/2019)... ... ... Twiggy Bean, Ph.D., wanted to educate others about the divorce bullying epidemic ... and become truly child focused. This objective prompted her to write “Divorce Bullying: An ... Don’t be a divorce bully!” (published by Balboa Press), a guidebook that serves as ...
Breaking Medicine Technology:
(Date:10/15/2019)... RICHMOND, Calif. (PRWEB) , ... October 14, 2019 , ... ... Network West to ride atop the Donate Life Rose Parade® float in the ... impacted by organ and tissue donation across Northern California and Northern Nevada, the organization’s ...
(Date:10/15/2019)... ... October 15, 2019 , ... Labeling for Prescription Drugs, ... **An FDAnews Webinar**, Tuesday, October 29, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/labelpredrug, ... new drug applications and biologics license applications? , How will the current content ...
(Date:10/15/2019)... ... October 15, 2019 , ... Genomenon® announced today at ... GENETICS that includes incorporating the Mastermind® Genomic Search Engine into the ... genomic research at the fingertips of clinical researchers performing genomic analysis worldwide. ...
(Date:10/11/2019)... ... ... Only 6% of orthopedic surgeons in the country are women – and ... the sports medicine program. These four work with a whole host of women providing ... , Orthopedic medicine deals with the correction of differences in bones or ...
(Date:10/11/2019)... ... ... A Topping Out event was hosted today at the construction site of the Southwest ... event celebrated reaching the final height of the structure set to open in the ... in Texas, STA’s facility will be home to an organ recovery center including a ...
Breaking Medicine News(10 mins):